Evidence map›Paper›PMID 31982938›Full record

ArticleActa neuropathologica2020

ACE2 activation protects against cognitive decline and reduces amyloid pathology in the Tg2576 mouse model of Alzheimer's disease.

Charles E Evans, James S Miners, Giulia Piva, Christine L Willis, David M Heard, Emma J Kidd, Mark A Good, Patrick G Kehoe

Erratum issuedOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta neuropathologica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 88 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
88citing papers in PubMed, 2 pooled it
15.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

88 citing papers in PubMed, 2 syntheses or guidelines pooled it, 154 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Current updates on latest basic research of scientific relevance in hypertensive dementia.Hypertension research : official journal of the Japanese Society of Hypertension · 2026
    Review
  7. Microglial activation and RAS signaling: a dual-edged sword in neuroinflammation.American journal of physiology. Regulatory, integrative and comparative physiology · 2026
    Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. The Contribution of the Renin-Angiotensin System to Alzheimer's Disease.Current topics in behavioral neurosciences · 2025
    Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article

28 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Charles E EvansSchool of Psychology, Cardiff University, Cardiff, CF10 3AT, UK.
James S MinersDementia Research Group, Translational Health Sciences, Bristol Medical School, University of Bristol, Level 1 Learning and Research, Southmead Hospital, Bristol, BS10 5NB, UK. scott.miners@bristol.ac.uk.ORCID http://orcid.org/0000-0001-8594-1640
Giulia PivaSchool of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, CF10 3NB, UK.
Christine L WillisSchool of Chemistry, University of Bristol, Cantock's Close, Bristol, BS8 1TS, UK.ORCID http://orcid.org/0000-0002-3919-3642
David M HeardSchool of Chemistry, University of Bristol, Cantock's Close, Bristol, BS8 1TS, UK.ORCID http://orcid.org/0000-0003-3005-8222
Emma J KiddSchool of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, CF10 3NB, UK.ORCID http://orcid.org/0000-0001-5507-1170
Mark A GoodSchool of Psychology, Cardiff University, Cardiff, CF10 3AT, UK.ORCID https://orcid.org/0000-0002-1824-1203
Patrick G KehoeDementia Research Group, Translational Health Sciences, Bristol Medical School, University of Bristol, Level 1 Learning and Research, Southmead Hospital, Bristol, BS10 5NB, UK. Patrick.Kehoe@bristol.ac.uk.ORCID http://orcid.org/0000-0002-7542-1139
Cardiff University · GBSouthmead Hospital · GBUniversity of Bristol · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mid-life hypertension and cerebrovascular dysfunction are associated with increased risk of later life dementia, including Alzheimer's disease (AD). The classical renin-angiotensin system (cRAS), a physiological regulator of blood pressure, functions independently within the brain and is overactive in AD. cRAS-targeting anti-hypertensive drugs are associated with reduced incidence of AD, delayed onset of cognitive decline, and reduced levels of Aβ and tau in both animal models and human pathological studies. cRAS activity is moderated by a downstream regulatory RAS pathway (rRAS), which is underactive in AD and is strongly associated with pathological hallmarks in human AD, and cognitive decline in animal models of CNS disease. We now show that enhancement of brain ACE2 activity, a major effector of rRAS, by intraperitoneal administration of diminazene aceturate (DIZE), an established activator of ACE2, lowered hippocampal Aβ and restored cognition in mid-aged (13-14-month-old) symptomatic Tg2576 mice. We confirmed that the protective effects of DIZE were directly mediated through ACE2 and were associated with reduced hippocampal soluble Aβ

Indexed as

Alzheimer DiseaseAmyloidogenic ProteinsAngiotensin-Converting Enzyme 2AnimalsCognitive DysfunctionDiminazeneDisease Models, AnimalMiceMice, TransgenicProto-Oncogene MasAce2 protein, mouseAmyloidogenic ProteinsAngiotensin-Converting Enzyme 2Diminazenediminazene aceturateProto-Oncogene MasACE2Alzheimer’s diseaseAngiotensin-(1–7)DIZEMasRRenin–angiotensin system

Identifiers

PMID31982938
PMCPMC7035243
OpenAlexW3002254006

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.